Plandai Biotechnology, Inc. Highlighted in Newly Published Article by South Africa’s Department of Science & Technology
SEATTLE, WA–(Marketwired – December 01, 2014) – Plandaí Biotechnology, Inc. (PLPL) (“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the Company has been highlighted in an article titled “‘Secret’ Technology Turns Local Farm into Green Tea Extract Factory” in the December edition of the Republic of South Africa’s Department of Science & Technology: Public Understanding of Biotechnology Newsletter. The article, which was reviewed by independent experts through the South African Agency for Science and Technology Advancement (SAASTA) Scientific Editorial Process, can be found at: https://www.pub.ac.za/newsletter/02-201412/article-1.html.
The Department of Science and Technology launched a Public Understanding of Biotechnology (PUB) program to ensure a clear, balanced understanding of the scientific principles, related issues and potential of biotechnology and to stimulate public debate around its applications in society. In its monthly newsletter, the Department covers a variety of topics and issues that help to further educate the public in biotechnology.
December’s PUB newsletter offers a full feature article that looks into Plandaí’s efforts to bring the once abandoned Senteeko Tea Estate back to life, the growing and harvesting process of the Company’s green tea and other plants, the “secret” technology employed at Plandaí, an interview with the Company’s President and CEO, Roger Duffield, the work to bring higher bioavailability extracts to market, and much more.
In an excerpt from the article, the author writes, “That farm was abandoned.” Duffield recalls. “The tea bushes were 20 feet high, the roads didn’t exist and the old tea factory had been ransacked with the roofs caved in and owls nesting in it.”
A few years…later, the Senteeko estate in the Barberton District of Mpumalanga is now a lush and neatly-maintained tea farm hidden deep within hundreds of hectares of Sappi paper plantations, with Plandaí’s brand new, on-site agro-processing facility soon to ship its first batch of Phytofare™ Catechin Complex from green tea.
Access the article at: https://www.pub.ac.za/newsletter/02-201412/article-1.html.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit https://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com